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Human parvovirus B 19 was discovered in 19751. The
first clinically significant illness associated with B 19
infection was hypoplastic crisis in children with
sickie-cell anaemia2. Development of specific
serological assays showed that patients with fifth
disease (erythema infectiosum) also had acute B19
infection3; an aetiology that is now widely accepted.
Human parvovirus B 19 is a member of the genus
Erythrovirus of the family Parvoviridae. B19 is a small
single-stranded DNA virus, whose genome is a single
linear molecule of only 5596 nucleotides; composed
of an internal coding sequence of 4830 nt, flanked by
the terminal repeat sequences of 383 nt each. The
major nonstructural protein, NS 1, is encoded by the
left side of the genome, and is essential for viral
replication. Structural proteins, VP1 and VP2, are
encoded by the right side of the genome and form the
viral capsid. Parvovirus B 19 has not been shown to
infect other animals, and the other animal
parvoviruses have not been shown to infect humans.
B 19 infection is common in humans, with a
seroprevalence in developed countries of 5% in
children, 60% in blood donors and 85% or more in the
elderly. In temperate climates, there is an increased
prevalence from late winter to early summer and
increased infection rates every four to five years. B 19
is transmitted in the community by the respiratory
route causing infection both sporadically and in
outbreaks, which are apparent in schools.
Transmission has also occurred among medical
laboratory staff working with native virus. B 19 virus
can also be found in donated blood, the incidence of
which is estimated between 1:3300 and 1 :50,000, and
infection has been transmitted by clotting factor
concentrates. Although nosocomial transmission and
resultant outbreaks in both paediatric and adult wards
have been documented, this is infrequent 4.
B 19 infection may be asymptomatic or may result in a
wide range of clinical manifestations depending on
host factors such as age, presence of anti-B 19
antibody, immunocompetence and red cell fragility.
B 19 is the aetiological agent of erythema infectiosum,
transient aplastic crisis in patients with shortened red
cell survival, acute and chronic arthritis and chronic
anaemia in immunocompromised patients. B 19
infection has also been associated with fetal hydrops,
congenital red cell aplasia, vasculitis syndromes,
glomerulonephritis with nephrotic syndrome,
meningitis, encephalopathy, peripheral neuropathy,
myocarditis, hepatitis, systemic lupus erythematosus,
necrotising histiocytic lymphadenitis (Kikuchi's
disease), pulmonary disease following paediatric heart
transplantation, conjunctivitis, Kawasaki disease,
congenital abnormalities and chronic fatigue
syndrome4
An outbreak of B19 infection in Northern Ireland
My work began with the description of an outbreak of
B19 infection in Northern Ireland. Testing patient
serum using an in-house enzymeimmunoassay assay
(EIA) for anti-B19 IgM, 133 cases of acute B19
infection were diagnosed by the Regional Virus
Laboratory from 1984 to July 1991. An increased
prevalence (103 of 133 cases) occurred during 1989-
1990. Of the total 133 cases, the ratio of female to
male was 3.4: 1. The age range was 4-63 years with a
mean of 28 years. Clinical manifestations of infection
from 1984 - 1991 included rash (n=22), arthralgia
(n=35), rash and arthralgia (n=70), aplastic crisis in
patients with shortened red cell survival (n=3), fetal
death following maternal infection (n=l), Henoch-
Schonlein purpura (n=1), and lymphadenopathy
(n=l). This outbreak coincided with an outbreak in
England and Wales'.
Study of the incidence of fetal death in B19-infected
pregnant women.
Although B 19 was known to cause fetal death, the
incidence of this following maternal B 19 infection
was unknown. During 1989, the outbreak year, we
collected and later tested the serum from 2400
pregnant women at 12 weeks gestation for the
presence of anti-B 19 IgM by enzymeimmunoassay.
Eight of these were positive. We followed these
pregnancies and found that one resulted in
spontaneous abortion at 26 weeks. The incidence of
fetal death following maternal infection was therefore
12.5%, in general agreement with the major UK study
of 186 pregnancies which showed a 9.2% incidence of
fetal death. No congenital abnormalities were noted in
the 7 surviving infants, either at birth or at 3 years of
age5.
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TABLE
Clinical details and results ofserum PCRfor B19 DNA from seven patients with persistent Bl9 infection at
acute infection and atfollow-up assessment. Genotyping of these B19 isolates is shown in Figure 2. (see
reference numbers 16 & 17).
Patient Age Sex Symptoms B19 DNA at Follow-up Duration of Symptoms at B19 DNA at
number onset at onset onset interval symptoms follow-up follow-up
(months) (months)
24 10 F Rash NT 55 <1 - +
39 49 F Arthralgia in knees + 61 <1 - +
40 29 F Arthralgia in knees + 61 61 Arthralgia in knees +
41 54 F Rash + 60 <1 - +
46 22 F Rash NT 50 <1 - +
50 29 F Aplastic crisis + 26 26 Chronic haemolytic +
anaenia
51 17 F Arthralgia in knees NT 65 65 Arthralgia in knees and +
and shoulders shoulders, Chronic
fatigue syndrome
NT not tested.
Production of a monoclonal antibody to B19 capsid
proteins
A highly conserved B 19 epitope is known to be
encoded by amino acids 328 - 344 of B 19 viral Protein
2. Antibody attachment to this epitope neutralises the
virus in erythroid culture.
Using avidin-biotin immunohistochemistry, 3H8
labelled erythroid cells with and without viral
inclusions in lung sections from 4 fetuses with
histology suggestive of intrauterine B 19 infection. No
staining was observed in other cell types or fetal lung
sections from negative controls. The isotype of 3H8
was IgGl6.
Study of the cellular distribution of blood group P
and B19 antigens in B19 infected bone marrow
In 1993, blood group P antigen was implicated as the
cellular receptor for parvovirus B 197. In response to
this, we examined the bone marrow of 61 AIDS
patients and selected 3 bone marrow biopsies which
were positive for B 19 DNA by nested PCR and B 19
capsid proteins by avidin-biotin immunohisto-
chemistry using monoclonal antibody, 3H8. These
sections were then stained by a double-fluorescent
labelling technique using 3H8 linked to Texas Red
followed by a monoclonal antibody to P antigen linked
to fluorescein. In all 3 cases an identical pattern of
cellular distribution of the two antigens was seen,
providing further evidence for P as the virus receptor
(Figure 1)8.
Study of the molecular epidemiology of parvovirus
B19
The dominant influences on the clinical manifestations
of B 19 infection are those of the host. Namely, age,
presence of anti-B 19 antibody, immunocompetence,
red cell fragility, and blood group P antigen status.
However, it is possible that the make-up of a particular
B 19 strain may also contribute9. To study the
molecular epidemiology of B 19 infection, we
developed a viral typing method using PCR - single-
stranded conformational polymorphism (SSCP) assay.
A nested PCR method was developed using
oligonucleotide primers specific for a region within
the B 19 non-structural gene. The first reaction
amplified a 369 bp fragment, and the second amplified
an internal 284 bp fragment (B19 nucleotides 1399-
1682). This 284 bp fragment, after visualisation on
agarose gel electrophoresis was then typed using
SSCP. The principle of SSCP is that electrophoretic
mobility of a DNA molecule in a gel is sensitive to
both its size and shape. Therefore, a mutated sequence
causes altered folding which is detected as a change in
mobility. And in general, the method has a higher
sensitivity for short fragments of 100 - 200 bases'0.
The method was optimised to 100% sensitivity, and
was able to detect a single mutation in the 284 bp
fragment. The method was then applied to 50 virus
isolates from patients with different symptoms and
geographical locations.
Five types were demonstrated, each of which had a
unique nucleotide sequence. In all, 6 mutations were
detected, all of which were silent, consistent with the




Figure la. B19 infected bone marrow. stained sequentially with
monoclonal antibody to B19 antigen (3H8) linked tofluorescein
and monoclonal antibody to blood group P antigen (a-P) linked
to texas red. Figures la and lb were viewed with filters of
emission wavebands at 515nm (to detect bound Streptavidin -
FITC) and 615nm (to detect bound Streptavidin - Texas Red),
respectively. Both monoclonal antibodies show the same pattern
of cellular distribution (see reference number 8).
conserved nature of this region and its crucial role in
B 19 replication. Among the 50 isolates, types 3 and 4
accounted for 92%. A correlation was seen between
SSCP type and country of origin. Type 3 predominated
in Japan and the UK, whereas type 4 predominated in
the USA. Also, type 3 strains predominated among
females, whereas there were approximately equal
numbers of strain types 3 and 4 among males, a
finding which remains to be explained. Within the
Japanese group, although type 3 strains predominated
overall, strains isolated from 1981 to 87 consisted of
types 1,2, 3, and 4, whereas strains isolated from 1990
to 94 consisted almost entirely of type 3. There was no
correlation between SSCP type and clinical illness 11.
Study of the role of B19 in the pathogenesis of
rheumatoid arthritis
B19 arthiralgia occurs in up to 80% of infected adults,
affecting the hands, wrists, knees, and cervical spine.
Most patients are women, and rheumatoid factor may
be present or may rise following B19 infection. B19
DNA has been detected in the synovial fluid, cells, and
tissue of patients with serologically proven B 19
infection. On this basis, B 19 was implicated in the
pathogenesis of RA.
First, we hypothesised that if B 19 plays a role in RA,
then rheumatoid synovium would contain B 19 DNA
significantly more frequently than controls. We
examined 52 patients undergoing elective orthopaedic
surgery; 26 test patients with RA and 26 controls with
osteoarthritis (OA)
All synovia were negative for both antigens. Using
nested PCR to detect B 19 DNA, all sera were
negative. However, in synovium,10 of 26 RA patients
and 9 of 26 OA patients were positive (P = 0.77). All
patients with B19 DNA in synovium had serum anti-
B19 IgG'2.
Second, we hypothesised that if B19 plays a role in
RA, then RA patients at the time of acute joint
swelling may exhibit B 19 DNA in the serum, synovial
fluid and synovial fluid cells significantly more
frequently than controls. A total of 29 patients with
acute joint swelling requiring knee joint aspiration
were assessed; 18 test patients had RA, and 11 control
patients had non-rheumatoid (non-RA) disease.
Serum and synovial fluid from au patients from both
groups were anti-B 19 IgM negative. Serum, synovial
fluid and synovial fluid cells from all patients tested
negative for serum B 19 DNA"3. From, these 2 studies,
we concluded that a role for B 19 in the pathogenesis
of RA was not supported.
Presence of viral DNA in synovium is not indicative
of viral replication unless intracellular B19 protein is
also identified. P antigen was looked for in synovial
sections as it might act as the viral receptor in synovial
cells, as it does in erythroid cells. However, since P
was not detected in any case, the mechanism of viral
entry into these cells is unclear. In addition, in vitro
cultures of human synovial cells are resistant to B19
infection. There are therefore two theories which may
account for a persistent arthropathy following B19
infection and possibly also the presence of B 19 DNA
in synovium. First, as the joint symptoms coincide
with appearance of specific IgG, viral persistence may
occur in an extraarticular site such as the bone marrow,
with prolonged symptoms being generated by
immunopathological mechanisms. Intermittent
viraemia may contaminate synovium and explain
positive PCR results. However against this, in the
present study all 52 sera were PCR-negative. Second,
local viral replication may occur in another cell type,
for example the macrophage, with excretion of a factor
causing synovial inflammation. The Bl19 non-
structural protein, NS1, would be a candidate as it is
cytotoxic in vitro'2.
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Figure 2. SSCP analysis ofPCR products from the serum of 7
patients with persistent B19 infection (Table). Each specimen
showed double-stranded DNA of284bp (nt 1399 to nt 1682) on
conventional agarose gel electrophoresis. PCR products were
denatured at 90'C informamide and subjected to electrophoresis
in a Mutation Detection Enhancement acrylamide gel (AT
Biochem) in 90mM Trisborate, pH 8.3 /4mM EDTA at a constant
power of2OWfor 5 hours at 23 C in a vertical gel
electrophoresis apparatus (Bio-Rad). The gel was stained by a
silver staining method (Promega), and viewed and photographed
on a light box (see reference numbers 16 and 17). Reproduced
with permission of Scandinavian University Press.
Follow-up study of acute B19-infected persons
In immunocompetent persons, prompt viral clearance
and disease resolution is the rule. However, reports
have described persistent B 19 infections in apparently
normal persons and an association with autoantibody
production and autoimmune disease. These reports
prompted us to perform a follow-up study in 53
persons with confirmed B 19 infection and without a
known immune defect, to determine the natural
history, immune response, and incidence and
significance of autoantibody production and virus
persistence. Fifty-three patients testing positive for
serum anti-B 19 IgM were followed for approximately
4 years. At follow-up, clinical symptoms were
recorded and blood taken. A control group was
included, matched for age and sex.
Seven patients presenting with rash had resolved
within a month. Of 42 cases of arthralgia, 19 had
resolved within a month, and 23 persisted for 1-7
years. In two cases with persistent arthralgia, chronic
fatigue syndrome (CFS) was also present. Of 3
patients presenting with aplastic crisis, 2 were
asymptomatic at follow-up and one required
occasional blood transfusion for a chronic anaemia.
There was one case of fetal death following materal
infection. Apart from one patient with persistent
arthralgia who had been diagnosed as having
rheumatoid arthritis, there were no cases with other
symptoms suggestive of autoimmune disease. At
follow-up, all test and control patients were serum
anti-B19 i1gM negative. All 53 test patients and 45
controls were IgG positive (2-tailed P value = O.OO8)'.
These sera were then tested for antibodies to the
unique region ofBp19 VP. B19 structural proteins,
VP1 and VP2, form the viral capsid in a ratio of 1:25,
respectively.wi Theyare ieantical -excpt for an
paddtional 227seamino acids atpheamtino-trmsinalofer
VP1mpthio-atcalle uniqowueVP1 rgoneproetsirom
Thevrusw urfae ando ietslreontiolowngbytehmatena
immune system is crucial in disease resolution. Serum
was tested for antibodies to this region by
immunoblot, using 11 synthetic overlapping peptides
incorporated onto nitrocellulose strips. At follow-up
all test and control patients were negative for
antibodies to this region. Serum from the time of acute
infection was available for 33 test patients, 16 of
which were positive. However, presence or absence of
these antibodies did not predict particular symtoms of
their duration. Of the 11 peptides, 3 were variably
recognised; numbers 2, 8 and 9. These peptides
correspond to 2 regions, which encode neutralising
viral epitopes. Although, immune recognition of this
region is crucial in disease resolution surprisingly all
patients tested negative for these antibodies at
convalescence. The most likely explanation may be
that while antibody binding of these linear epitopes
may neutralise the virus, the most important
neutralising epitopes are conformational and therefore
undetectable in an immunoblot14.
Seven test and no control patients had serum
autoantibody at a titre greater than or equal to 160.
These antibodies consisted of antinuclear, gastric
parietal cell, antireticulin, antmitochondrial and
rheumatoid factor. Only one of these patients had
clinical illness at follow-up; a 48 year old woman with
serum rheumatoid factor of 1920 iu/ml and a 4 year
history of polyarthritis, who had been diagnosed as
having RA. In conclusion, in most cases it would seem
that these autoantibodies did not have clinical
relevance'5.
Serum was then tested for B 19 DNA by nested PCR.
Seven Test and no control patients were positive (2-
tailed P value = 0.016). All seven with persistent
infection were women, only 3 of which were
symptomatic with arthralgia, arthralgia and CFS and
chronic anaemia, respectively (Table). There was no
obvious relationship between B19 persistence,
autoantibody production and immune recognition of
the unique region of VP1. For the 7 persistently
infected patients, serum from the time of acute
infection was available for four, all of which contained
B19 DNA. SSCP assay (Figure 2) showed identical
types in 5 of 7 follow-up isolates, suggesting an
advantage to the virus of this particular type. In 2 of
the 4 cases for which both acute and follow-up PCR
product was available patient numbers 40 and 41, the
SSCP type at follow-up was different from that at
presentation, demonstrating nucleotide substitution
occurring during persistent infection. In addition, 2
virus types were shown to co-exist in patient 51, with
chronic fatigue syndrome (Figure 2). This is a
phenomenon not previously demonstrated for B 19 but
known to occur with Aleutian mink disease
parvovirus, which is also prone to persistent
infections. We speculated that as Bl19 non-structural
protein is required for replication, DNA sequence
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changes in this region may modify viral replication,
possibly promoting persistence'6 7.
Study of the role of B19 in chronic fatigue
syndrome
Results of the follow-up study indicated that 2 of 53
patients with acute B19 infection developed CFS,
which was still present after 4 years. One of these
patients was shown to be persistently infected, and
SSCP assay showed the co-existence of 2 virus types.
In view of this we examined serum from 22 cases of
CFS, according to the diagnostic criteria of the Centers
for Disease Control, and 12 normal controls.
Regarding serum ant-B 19 IgM, 3 of 22 test and 2 of 12
control cases were positive; a surprising result,
although not statistically significant. Regarding serum
anti-B 19 IgG, 15 of 22 test and 8 of 12 control cases
were positive; again not significant. All test and
control cases were PCR-negative.
We also tested muscle biopsies from 6 patients with
CFS and 6 control persons for B 19 DNA by nested
PCR; one of each group was positive, a non-
significant difference'8. From these 2 studies, we
concluded that a role for B19 in the pathogenesis of
CFS was not supported.
Study of B19 infection in HIV-1 infected patients
Acute B19 infection in AIDS patients may lead to
persistent infection and bone marrow suppression.
Persistent B19 infection is typically manifest by pure
red cell aplasia, and is associated with a lack of
humoral responsiveness to the unique region of VP1.
Human immunoglobulin, containing these antibodies,
is the only specific treatment. To determine the
incidence and significance of B19 infection in AIDS,
we tested the bone marrow and assessed the clinical
status of 61 HIV infected patients. Reasons for bone
marrow biopsy were investigation of anaemia, various
cytopenias and suspected lymphoma. The bone
marrow of 23 control patients assumed to be HIV
negative was also examined. Bone marrow biopsy had
been performed in these patients for investigation of
lymphoma, leukaemia, anaemia, platelet abnorm-
alities, multiple myeloma, and raised serum IgM.
13 test and no control patients had B 19 DNA detected
in bone marrow by nested PCR (2-tailed P value =
0.016). Of the 13 infected patients, 11 were CDC
group 4, reflecting the known correlation between B 19
persistence and level of immunosuppression. However
surprisingly, only 2 of these 13 had a haemoglobin
below 9g/dl.
One explanation may be that the virus is present at
very low concentration in bone marrow, as in all cases
it was detected only by nested and not by one-step
PCR. The sensitivity of the nested PCR was of the
order of 10 genome copies per ml. While the
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sensitivity of the one-step PCR was of the order of
100,000 genome copies per ml. Unfortunately, serum
from the time of bone marrow biopsy was unavailable.
Our conclusion, which is consistent with studies using
serum, is that low titre B19 persistence in the bone
marrow may be common and frequently subclinical in
AIDS patients 19.
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